Go back

Counting the cost of drug price negotiations

Image by Grace Gay for Research Professional News

Will R&D be devastated by US moves to control pill prices?

Progress on tackling cancer will slow down as investment in research is cut. Access to medicines will be restricted. And the time it takes innovative treatments to reach patients will grow and grow.

This is the bleak picture for medical research that the pharmaceutical industry claims is coming as a result of president Joe Biden’s administration allowing Medicare to conduct price negotiations on 10 drugs.

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.